KIT mutation in mucosal / acral / chronic-sun-damaged melanoma (~15-20% of these subtypes...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-KIT-MUTATION-MELANOMA |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MELANOMA |
| Sources | SRC-CIVIC SRC-ESMO-MELANOMA-2024 SRC-NCCN-MELANOMA-2025 |
Actionability Facts
| Biomarker | BIO-KIT |
|---|---|
| Variant | activating mutation (exon 11 / 13 / 17 — enriched in mucosal/acral melanoma ~15-20%) |
| Disease | DIS-MELANOMA |
| ESCAT tier | IB |
| Recommended combinations | imatinib (off-label / NCCN-supported for IO-refractory KIT-mutant melanoma exon 11 L576P / exon 13 K642E), anti-PD-1 ± anti-CTLA-4 (1L irrespective of KIT status) |
| Evidence summary | KIT mutation in mucosal / acral / chronic-sun-damaged melanoma (~15-20% of these subtypes; rare in cutaneous CSD-low): imatinib has activity (Carvajal JCO 2013; Hodi JCO 2013 — ORR 16-23% in selected KIT-mutant melanoma). Exon 11 L576P and exon 13 K642E are the most imatinib-responsive variants. Modern frontline is immunotherapy (anti-PD-1 ± anti-CTLA-4); imatinib is reserved for IO-refractory or IO-ineligible KIT-mutant disease. |
Notes
ESCAT IB. OncoKB Level 2. Trial-source gap: SRC-CARVAJAL-KIT-MELANOMA-2013 / SRC-HODI-2013 not yet ingested. KIT-mutant melanoma is also a scenario where dabrafenib/trametinib does NOT apply (BRAF V600 testing should be parallel).
Used By
No reverse references found in the YAML corpus.